Cidara Therapeutics, Inc.

CDTX

US1717572069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
12.02 ^USD	+0.84%		+0.17%	-24.31%

May. 15	Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	MT
Apr. 25	Top Premarket Gainers	MT

Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

April 23, 2024

On April 24, 2024, Cidara Therapeutics, Inc. closed the transaction.

Latest news about Cidara Therapeutics, Inc.

Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	May. 15	MT
Top Premarket Gainers	Apr. 25	MT
North American Morning Briefing : More Tech -2-	Apr. 25	DJ
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	Apr. 25	DJ
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
Transcript : Cidara Therapeutics, Inc. - Special Call	Apr. 24
Cidara Therapeutics, Inc. Announces Board Changes	Apr. 24	CI
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	Apr. 23	CI
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	Apr. 23	CI
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	Apr. 23	MT
Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	Apr. 22	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	Apr. 22	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split	Apr. 22	MT
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment	Jan. 30	MT
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	CI
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $12.7M	Nov. 02	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI

Chart Cidara Therapeutics, Inc.

Duration

Period

More charts

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Companyâs portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cidara Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.92 USD

Average target price

25 USD

Spread / Average Target

+109.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CIDARA THERAPEUTICS, INC.	-24.31%	54.38M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs